AAAAAA

   
Results: 1-7 |
Results: 7
BOOSTER IMMUNIZATION OF HIV-1 NEGATIVE VOLUNTEERS WITH HGP-30 VACCINEINDUCES PROTECTION AGAINST HIV-1 VIRUS CHALLENGE IN SCID MICE
Authors: SARIN PS TALMADGE JE HESELTINE P MURCAR N GENDELMAN HE COLEMAN R KELSEY L BECKNER S WINSHIP D KAHN J
Citation: Ps. Sarin et al., BOOSTER IMMUNIZATION OF HIV-1 NEGATIVE VOLUNTEERS WITH HGP-30 VACCINEINDUCES PROTECTION AGAINST HIV-1 VIRUS CHALLENGE IN SCID MICE, Vaccine, 17(1), 1999, pp. 64-71
CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL
Authors: KAHN JO STEIMER KS BAENZIGER J DULIEGE AM FEINBERG M ELBEIK T CHESNEY M MURCAR N CHERNOFF D SINANGIL F
Citation: Jo. Kahn et al., CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL, The Journal of infectious diseases, 171(5), 1995, pp. 1343-1347
ONE-YEAR FOLLOW-UP OF A PHASE-1 STUDY OF HIV-1 GP120 VACCINE COMBINEDWITH MF59 AND WITH A DOSE-ESCALATION OF MTP-PE IN HIV-1 NONINFECTED ADULTS
Authors: KAHN J CHERNOFF D SINANGIL F BAENZIGER J MURCAR N COLEMAN R WYNNE D LEE D HESTERMAN K SAKAMOTO D CUISON G DEKKER C STEIMER KS
Citation: J. Kahn et al., ONE-YEAR FOLLOW-UP OF A PHASE-1 STUDY OF HIV-1 GP120 VACCINE COMBINEDWITH MF59 AND WITH A DOSE-ESCALATION OF MTP-PE IN HIV-1 NONINFECTED ADULTS, AIDS research and human retroviruses, 10, 1994, pp. 190000155-190000155
CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS
Authors: KAHN JO SINANGIL F BAENZIGER J MURCAR N WYNNE D COLEMAN RL STEIMER KS DEKKER CL CHERNOFF D
Citation: Jo. Kahn et al., CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS, The Journal of infectious diseases, 170(5), 1994, pp. 1288-1291
PHASE-1 DOSE-ESCALATION MTP-PE STUDY OF AN HIV-1 GP120 VACCINE IN SERONEGATIVE ADULTS
Authors: KAHN J CHERNOFF D SINANGIL F MURCAR N WYNNE D COLEMAN R STEIMER K DEKKER C
Citation: J. Kahn et al., PHASE-1 DOSE-ESCALATION MTP-PE STUDY OF AN HIV-1 GP120 VACCINE IN SERONEGATIVE ADULTS, AIDS research and human retroviruses, 9, 1993, pp. 190000112-190000112
A PHASE-I DOSE-RANGING TRIAL OF HGP-30 CANDIDATE VACCINE IN HIV SERONEGATIVE ADULTS
Authors: COLEMAN R STITES D MURCAR N SARIN P GOLDSTEIN A HESELTINE P SIMON V KAHN J
Citation: R. Coleman et al., A PHASE-I DOSE-RANGING TRIAL OF HGP-30 CANDIDATE VACCINE IN HIV SERONEGATIVE ADULTS, Journal of cellular biochemistry, 1993, pp. 76-76
PHASE-STUDY OF AN HIV-1 GP 120 VACCINE COMBINED WITH THE NOVEL ADJUVANT EMULSION, MF59 AND THE BIOLOGIC RESPONSE MODIFIER MTP-PE IN HIV SERONEGATIVE ADULTS
Authors: KAHN J CHERNOFF D SINANGIL F BAENZIGER J MURCAR N WYNNE D COLEMAN R STEIMER K DEKKER C
Citation: J. Kahn et al., PHASE-STUDY OF AN HIV-1 GP 120 VACCINE COMBINED WITH THE NOVEL ADJUVANT EMULSION, MF59 AND THE BIOLOGIC RESPONSE MODIFIER MTP-PE IN HIV SERONEGATIVE ADULTS, Journal of cellular biochemistry, 1993, pp. 79-79
Risultati: 1-7 |